Jump to content
Atra

FDA grants Breakthrough Therapy designation to psylocibin as therapy for TRD

Recommended Posts

Research into psylocibin's efficacy in treating treatment resistant depression has been conducted in the US and UK before. This past week the US Food and Drug Administration granted the Breakthrough Therapy designation to Compass Pathways. 

This is news because now the company can perform larger clinical trials both in UK and US and if the results are promising, speed up access to patients by partnering with the FDA as opposed to fighting it. 

My diagnosis is MDD/TRD so I'll be following this closely. 

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×